Here are 1-2 brief analogies for ELAB:

• The Augustinus Bader of physician-dispensed skincare, leveraging proprietary exosome technology.

• Think of it as SkinCeuticals or ZO Skin Health, but specializing in advanced stem cell exosome-based formulations for professional aesthetic use.

• Topical Skincare Products with Elevai Exosomes™: Physician-dispensed cosmetic solutions infused with proprietary stem cell-derived exosomes, designed to topically enhance the appearance of skin and address common cosmetic conditions.

PMGC (ELAB) primarily operates on a business-to-business (B2B) model. Its major customers are:

• Physicians
• Medical aesthetics practices and clinics

These customers acquire ELAB's proprietary stem cell-derived Elevai Exosomes™ skincare products for dispensing to their patients and clients. The provided background information does not list the specific names of these customer companies, nor are these types of businesses typically public entities with stock symbols.

Graydon Bensler, Chief Executive Officer & Chief Financial Officer

Graydon Bensler was appointed as the non-employee Chief Executive Officer of PMGC Holdings Inc. (formerly Elevai Labs Inc.) on June 21, 2024, while also continuing to serve as the Chief Financial Officer until a successor is identified. He has served as a Director of Redwood AI Corp. and has been an Independent Director of AquaBounty Technologies, Inc. since October 28, 2025. He previously served as a Director of Onco-Innovations Limited.

Dr. Jordan R. Plews, Co-Founder, Head of Elevai Skincare and Elevai Biosciences

Dr. Jordan R. Plews is a co-founder of Elevai Labs, Inc. He served as the Chief Executive Officer until his resignation on June 21, 2024, and now leads the company's subsidiaries, Elevai Skincare and Elevai Biosciences. Dr. Plews has a background in biochemical engineering and stem cell research, having completed his undergraduate and doctoral studies in the UK and a postdoc at Stanford University. He transitioned into the biotech industry, where he created products for researchers and clinicians, and has experience working at companies like Pfizer and Beckton Dickinson. He holds seven filed patents and approximately 25 filed trademarks.

Braeden Lichti, Co-Founder & Non-Executive Chairman of the Board

Braeden Lichti is a co-founder of ELEVAI Labs and serves as the Non-Executive Chairman of the Board. He is also noted as the founder of one other company.

Regulatory Classification Risk

PMGC's core business revolves around "physician-dispensed skincare products" that are explicitly stated as "not drug products or considered regenerative medicine, nor have any of our products received FDA approval." The company markets these products as "topical cosmetic solutions" to "enhance the appearance of skin." A significant risk lies in the potential for regulatory bodies, such as the FDA, to reclassify their exosome-infused products from cosmetics to drugs or regenerative medicine. Such a reclassification would subject PMGC to substantially stricter regulations, requiring extensive and costly clinical trials, prolonged development timelines, and potential halts in sales until the necessary approvals are obtained. This could severely impact the company's operational model and financial viability.

Intellectual Property and Patent Risk

The company's competitive advantage is heavily reliant on its proprietary technology, specifically "proprietary stem cell-derived Elevai Exosomes™" and its "Precision Regenerative Exosome Technology™ (PREx™)" which utilizes "advanced patent-pending stem cell processing technology." The "patent-pending" status indicates that the intellectual property is not yet fully secured. There is a inherent risk that the applications for these patents may not be granted, or if granted, could be successfully challenged by competitors. A failure to secure or defend these patents could allow competitors to replicate or develop similar technologies, thereby eroding PMGC's unique market position and competitive advantage.

The primary clear emerging threat for ELAB is the potential reclassification of its "stem cell-derived Elevai Exosomes™" topical products by regulatory bodies (e.g., FDA) from cosmetics to drugs or biologics. ELAB explicitly states its products are "not drug products or considered regenerative medicine," "nor have any of our products received FDA approval," and "Our cosmetic products are not intended to prevent, treat or cure diseases or medical conditions." The use of "stem cell-derived" components that "may modulate and support these natural cellular processes" for cosmetic benefits introduces a gray area that regulators could scrutinize more intensely as the market for such advanced biotech-cosmetic hybrids grows. A reclassification would necessitate lengthy, costly, and uncertain drug approval processes, fundamentally disrupting ELAB's current business model, market access, and commercialization strategy.

PMGC (ELAB) operates in several addressable markets with substantial sizes globally and in North America, primarily through its physician-dispensed, exosome-infused topical skincare products aimed at enhancing skin appearance and addressing signs of aging.

Physician-Dispensed Skincare Market

• The global physician-dispensed skincare products market was valued at approximately USD 17.43 billion in 2026 and is projected to grow to about USD 34.32 billion by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 7.82%.
• In 2025, the global market for physician-dispensed cosmeceuticals was valued at USD 8.37 billion, with projections to reach USD 13.84 billion by 2031 at an 8.82% CAGR.
• North America holds a significant share of this market, accounting for over 35% in 2025. Another estimate indicates North America held a 40.08% share in 2025.
• Specifically, the U.S. physician-dispensed cosmeceuticals market size was valued at USD 3.28 billion in 2025 and is projected to reach USD 3.54 billion in 2026.
• Anti-aging products constitute a major segment within the physician-dispensed skincare market, representing over 40% of the total market share in 2025.

Exosomes Skincare Market

• The global exosomes skincare market was valued at USD 418.26 million in 2024 and is anticipated to reach USD 1,160.84 million by 2032, with a CAGR of 12.68%. Other estimates place the global market at USD 417.8 million in 2025, growing to USD 809.5 million by 2032 at a CAGR of 9.9%.
• North America is a leading region in the global exosomes skincare market, holding approximately 45% of the market share in 2024. The North American market alone was valued at USD 188.14 million in 2024 and is projected to reach USD 523.55 million by 2032.
• Anti-aging treatments are a dominant application segment within the exosome skincare market, driven by consumer demand for regenerative beauty solutions.

Anti-aging Products Market

• The broader global anti-aging products market was valued at USD 55.8 billion in 2023 and is projected to reach USD 108.5 billion by 2033, growing at a CAGR of 6.9%. Other estimates for the global market include USD 55.66 billion in 2025, reaching USD 107.61 billion by 2033 with an 8.9% CAGR.
• North America contributed significantly to the anti-aging products market, accounting for 35.99% of the global market revenue in 2025.

Expected Drivers of Future Revenue Growth for PMGC (ELAB)

Over the next 2-3 years, PMGC (ELAB), formerly Elevai Labs, Inc., is expected to drive revenue growth through several key initiatives:

1. Continued Growth of the Elevai Skincare Division: The core Elevai Skincare division has demonstrated significant sales milestones, including a record $300K monthly revenue in November 2024, representing a 65% increase over the preceding four-month average. This growth is attributed to a strategic overhaul by new management in Q3 2024, focusing on sales culture transformation, optimized budgets, and improved marketing strategies, which are expected to continue yielding positive results.
2. Advancement and Commercialization of Biopharmaceutical Pipeline (Obesity Treatment): The company's subsidiary, Elevai Biosciences (now Northstrive Biosciences), is actively developing investigational products EL-22 and EL-32 for obesity treatment, specifically targeting muscle preservation during weight loss. The advancement of these candidates through preclinical and clinical trials, coupled with ongoing patent filings, represents a significant potential new revenue stream from the biopharmaceutical sector.
3. Launch of New Skincare Products and Clinical Advancements: PMGC continues to invest in innovation within its aesthetic skincare portfolio. Clinical trials for products like Elevai Enfinity™ have shown improvements in skin firmness and wrinkle reduction, indicating a pipeline of new, advanced topical cosmetic solutions that can contribute to future sales.
4. Strategic Acquisitions and Partnerships: The company's management has expressed a commitment to pursuing growth opportunities through strategic acquisitions and investments in the biotech, cosmetic, health, and wellness sectors. Additionally, collaborations, such as the one with Yuva Biosciences for obesity and diabetes treatments, and a pending acquisition of a U.S.-based IT custom packaging firm, are expected to expand the company's capabilities and market reach, thereby driving revenue.
5. International Market Expansion: Elevai Labs reported over $213K in international revenue for 2023, indicating an expanding global footprint for its products. Continued penetration into new international markets for its physician-dispensed skincare offerings is anticipated to be a driver of incremental revenue growth.